Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00156520|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : April 12, 2010
|Condition or disease||Intervention/treatment||Phase|
|Hemorrhage||Drug: aprotonin; epsilon aminocaproic acid||Phase 4|
Hide Detailed Description
Study subjects will be competent adult patients who are scheduled to undergo elective aortic valve surgery for severe aortic stenosis. The process of informed consent will begin prior to the day of surgery either during a patient's preoperative surgery clinic visit with one of the cardiac surgeons for any patient having such a clinic visit or during the preoperative anesthesia evaluation prior to the day of surgery. At one or both of these times patients will be told of the study and given a copy of the informed consent for their reading. An opportunity for them to discuss the study at this time will be offered. Written informed consent will be obtained on the day of surgery, prior to surgery. Patients must not also require coronary artery surgery or be taking or receiving drugs that alter platelet function, including aspirin (within the past 2 weeks) or any of the modern a ADP receptor antagonists such as Plavix. As per current patient care guidelines at Strong Memorial Hospital, patients undergoing first-time single valve, non-coronary artery surgical procedures will be randomized to receive either epsilon aminocaproic acid (EACA) or aprotonin intravenously. It is anticipated that 1-3 patients will be initially enrolled as pilot subjects to get the study going smoothly and that 1-3 patients may not be completed or that their testing and/or data may be inadequate. Therefore, although the analysis will only use 40 subjects the protocol seeks permission to enroll a maximum of 24 subjects per group for a total of 48 patients.
The tests to be performed are:
- the PFA-100, a platelet related hemostasis test which is a high shear system test of platelet function
- the von Willebrand antigen test, an immunoassay
- factor VIII coagulant activity test.
- Ristocetin cofactor activity test.
- thromboelastography (TEG), a point-of-care test of hemostatic function which includes a measure of platelet function.
(Reference ranges / coefficient of variation / SD's / for the tests are as follows:
vWF-Ag: 50 - 160% normal activity / 2 - 5% / ~5%
FVIII: 50 - 200% of normal / 4 - 7% / ~5%
Ristocetin cofactor: 60-200% of normal / ~15% / ~10%
PFA100 closure time: epinephrine <181 seconds and ADP <112 seconds / ~12% / 20 secs)
Total blood volume required from each patient for the purposes of doing the research related tests will be approximately 30 mls (1 fluid ounces or 2 tablespoons). 10 mls will be drawn from each patient's arterial line, which is routinely placed for cardiac anesthesia & surgery care, at the following time points in their care:
- prior to induction of anesthesia
- 5 minutes after the loading dose of either EACA or aprotonin has been administered and prior to the administration of any heparin
- 15 minutes after the administration of protamine following termination of cardiopulmonary bypass.
Thus, no additional "needle puncture" will be necessary related to the study. Each blood sample of 10 ml will be divided into one "blue-top" (citrated) tube (3 ml) and kept on ice, one "blue-top" (citrated) tube (3 ml) and kept at room temperature, and the remainder will be used to perform the TEG.
IV. Data Analysis and Monitoring:
Statistical analysis will be performed using either a 2-sample t-test or the Mann-Whitney Test, as appropriate, to compare the two patient groups at each of the three time points. A p-value of less than 0.05 will be considered significant. All tests will be two-sided.
With a proposed sample size of N = 20 for each of the two groups, the study will have at least 80% power to yield a statistically significant result.
V. Data Storage and Confidentiality:
Data will be produced within the SMH hematology lab and then stored both on paper and on the computer in the Department of Anesthesiology and backed up on the network drive.
The principal investigator will maintain the information in a password protected file on the computer in his (their) private office.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Jeanne Grace; Head Research Subjects Review Board|
|Study Start Date :||March 2005|
|Actual Study Completion Date :||September 2005|
- 1. the PFA-100, a platelet related hemostasis test which is a high shear system test of platelet functionPFA-100, a platelet related hemostasis test
- 2. the von Willebrand antigen test, an immunoassayvon Willebrand antigen test
- 3. factor VIII coagulant activity test.Factor VIII coagulant activity test
- 4. Ristocetin cofactor activity test.
- 5. thromboelastography (TEG), a point-of-care test of hemostatic function which includes a measure of platelet function.
- thromboelastographythromboelastography point of care test of hemostatic function
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00156520
|United States, New York|
|Strong Memorial Hospital, University of Rochester|
|Rochester, New York, United States, 14642|
|Principal Investigator:||Peter L Bailey, MD`||University of Rochester, Rochester, NY 14642|